SCHEMBL3564942

SCHEMBL3564942

CCOC(=O)c1cnc(C(C)(C)C)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
FOS P01100 1/20 0.47
JUN P05412 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
CA12 O43570 3/20 0.46
CA1 P00915 3/20 0.46
CA2 P00918 3/20 0.46
CA7 P43166 3/20 0.46
CA9 Q16790 3/20 0.46
CA14 Q9ULX7 3/20 0.46
ESR1 P03372 1/20 0.46
ESR2 Q92731 1/20 0.46
CYP1A2 P05177 2/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.44
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346837 0.84 FOS (0.49) CYP2C9CYP2C19FOSJUNNFKB1
SCHEMBL9785366 0.83 FOS (0.40) CYP2C9CYP2C19FOSJUNNFKB1
SCHEMBL2642000 0.81 CYP2C9 (0.53) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL6880667 0.79 CA12 (0.55) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL4595467 0.79 MAPK1 (0.52) NFKB1NFKB2RELACA12CA1
SCHEMBL9785451 0.79 FOS (0.38) CYP2C9CYP2C19FOSJUNNFKB1
SCHEMBL12868073 0.78 KMT2A (0.54) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL829286 0.78 CYP2C9 (0.50) CYP2C9CYP2C19NFKB1CA12CA1
SCHEMBL19779421 0.78 CA12 (0.53) CYP2C9CYP2C19CA12CA1CA2
SCHEMBL12461092 0.78 CYP2C9 (0.50) CYP2C9CYP2C19CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7666873-B2 N-phenyl-(2R,5S)dimethylpiperazine derivative ASTELLAS PHARMA INC. (JP) 2010-02-23 US disclosed
US-20080214543-A1 N-Phenyl-(2R,5S)Dimethylpiperazine Derivative ASTELLAS PHARMA INC. (JP) 2008-09-04 US disclosed
US-7297698-B2 N-phenyl-(2R,5S) dimethylpiperazine derivative ASTELLAS PHARMA INC. (JP) 2007-11-20 US disclosed
US-20050261303-A1 N-phenyl-(2r,5s) dimethylpiperadine derivative ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1557411-A1 N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261303-A1 N-phenyl-(2r,5s) dimethylpiperadine derivative BPHL, QDPR, SRD5A2 CYP2C9 1455/4885CYP2C19 1026/4885FOS 3285/4885
US-20080214543-A1 N-Phenyl-(2R,5S)Dimethylpiperazine Derivative BPHL, AR, SRD5A2 CYP2C9 2016/4885CYP2C19 1586/4885FOS 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.